Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
European Psychiatry 2025 Marianne Destoop, Pavel Mohr, Florence Butlen-Ducuing et al. 7 citations
Abstract Background Recent years show an exponential increased interest (“renaissance”) in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of...